Do NMPA Approvals Cause Share Prices to Rise?
施樱子 · 07/22/2021
three fourths of stocks to rise on the day of approval.
READ MORE
PharmaDJ
ADCs and Immuno-Oncology Therapies Attract Massive...
储旻华 · 07/12/2021
China Biotech Fundraising Tracker: May 2021
READ MORE
PharmaDJ
New Regulation Allows NDRL-Negotiated Drugs in Ret...
储旻华 · 07/12/2021
China Regulation Tracker: May 2021.
READ MORE
PharmaDJ
New CDE Guidelines Spur a Market Panic
储旻华 · 07/12/2021
Now, oncology is the hot field in drug development. Therefore, the CDE wants to guide clincial development through the document, emphasis the concept of clincial value-oriented, and implement the ICH PFDD guidelines through the document.
READ MORE
PharmaDJ
China Licensing Deals Tracker: May 2021
储旻华 · 07/08/2021
LianBio Acquires Three Potential FIC Therapies for Cancer and IBD.
READ MORE
PharmaDJ
China Market Approval Tracker: May 2021
储旻华 · 07/08/2021
The NMPA Grants Three Orphan Drugs Market Approval.
READ MORE
PharmaDJ
Key Takeaways from the CDE's 2020 Annual Drug Eval...
储旻华 · 07/08/2021
The amounts to a total increase of 32.67% from 2019 despite the pandemic.
READ MORE
PharmaDJ
China Approved its First Cell Therapy
施樱子 · 06/29/2021
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
READ MORE
PharmaDJ
NMPA Re-elected as ICH Management Committee Member...
研发客 · 06/29/2021
"The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future."
READ MORE
PharmaDJ
The Chinese Government is Taking Initiatives to En...
研发客 · 06/16/2021
Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner.
READ MORE
PharmaDJ
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明